Abeona Therapeutics, Inc. (ABEO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$6.00+1.18%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ABEO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Expand patient treatments, grow qualified treatment center network, and increase ZEVASKYN revenue steadily post-launch.
Stated as a priority in 2 of last 2 quarters. ZEVASKYN revenue grew from $8.7 million in 2026-Q1 to $11.4 million in 2026-Q2, a 31% quarter-over-quarter increase. The number of patients treated and qualified treatment centers expanded, indicating delivering commercial growth consistent with management's stated focus.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Steady launch-year growth for ZEVASKYN. Five patients treated with ZEVASKYN in Q2 2026; expanding QTC network now includes seven sites nationwide.”
“Steady increase in ZEVASKYN adoption with three patients completing treatment in Q1 2026; QTC network expands to six sites.”
Target to reach profitability in 1H 2026 driven by ZEVASKYN revenue growth and cost management.
Stated in 3 of last 3 quarters. Management targeted profitability in 1H 2026, but net losses were $(17.1) million in 2026-Q1 and $(20.2) million in 2026-Q2, indicating limited progress toward profitability so far despite revenue growth.
“Confidence in ZEVASKYN's opportunity reinforced by launch progress and experience to date.”
“Projected profitability in 1H 2026.”
“Despite a one-quarter shift in patient starts, we remain steadfast in our 2026 launch goals.”
Grow the network of QTCs to increase patient access and treatment capacity for ZEVASKYN.
Stated in 2 of last 2 quarters. The QTC network expanded from six sites in 2026-Q1 to seven sites by 2026-Q2/Q3 with new activations at major centers, supporting management's stated priority of expanding patient access and treatment capacity.
“NewYork-Presbyterian/Columbia and CHOP activated as QTCs in Q2 2026; Cincinnati Children’s activated in Q3 2026.”
“QTC network expands to six sites with two new additions on the East Coast.”
Focus development efforts on ABO-701 targeting PSMA for solid tumors with IND filing planned in 2H 2027.
Newly stated in 2026-Q1. Management announced focus on ABO-701 with IND filing planned in second half of 2027. No financial or clinical progress data yet available to assess delivery.
“In-licensed ABO-701, a novel engineered T-cell therapy targeting PSMA; IND filing planned in 2H 2027.”
Ensure sufficient cash runway to support operations before significant ZEVASKYN revenue contribution.
Stated in 2 of last 2 quarters. Cash and equivalents declined from $191.4 million at end 2025 to $146.8 million at mid-2026, consistent with funding operations over two years as planned. Management maintains focus on financial resources to support operations during commercial ramp.
“Cash, cash equivalents and short-term investments totaled $168.3 million as of March 31, 2026.”
“Expected to fund operations for over two years before anticipated ZEVASKYN revenue beginning in 3Q 2025.”
Over the trailing year it converted 0.81x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
6 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.